In vitro basal T-cell proliferation among asymptomatic Human T cell Leukemia Virus type 1 patients co-infected with hepatitis C and/or Human Immunodeficiency Virus type 1
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
HAZIOT, Michel E.
SMID, Jerusa
OLIVEIRA, Augusto Penalva de
NORRIS, Philip J.
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.22, n.2, p.106-112, 2018
Resumo
Background: Infection with Human T cell Leukemia Virus type 1 can be associated with myelopathy/tropical spastic paraparesis (HAM/TSP) and other inflammatory diseases. Lymphocytes from about half of Human T cell Leukemia Virus type 1-infected subjects spontaneously proliferate in vitro, and how this phenomenon relates to symptomatic disease and viral burden is poorly understood. Objective: To evaluate T-cell proliferation in vitro among patients co-infected with Human T cell Leukemia Virus type 1/Hepatitis C Virus/Human Immunodeficiency Virus type 1. Material and methods: From 610 Human T cell Leukemia Virus-infected patients of the Human T cell Leukemia Virus outpatient clinic from Institute of Infectious Diseases ""Emilio Ribas"" in Sao Paulo, 273 agreed to participate: 72 had HAM/TSP (excluded from this analysis) and 201 were asymptomatic, a classification performed during a regular neurological appointment. We selected the subgroup made up only by the 201 asymptomatic subjects to avoid bias by the clinical status as a confounder effect, who had laboratory results of Human T cell Leukemia Virus type 1 proviral load and T-cell proliferation assay in our database. They were further grouped according to their serological status in four categories: 121 Human T cell Leukemia Virus type 1 asymptomatic mono-infected carriers; 32 Human T cell Leukemia Virus type 1/Hepatitis C Virus, 29 Human T cell Leukemia Virus type 1/Human Immunodeficiency Virus type 1, and 19 Human T cell Leukemia Virus type 1/Human Immunodeficiency Virus type 1/Hepatitis C Virus co-infected patients. Clinical data were obtained from medical records and interviews. DNA Human T cell Leukemia Virus type 1 proviral load (PVL) and T-cell proliferation (LPA) assay were performed for all samples. Results: From a total of 273 subjects with Human T cell Leukemia Virus type 1, 80 presented co-infections: 29 had Human Immunodeficiency Virus type 1, 32 had Hepatitis C Virus, and 19 had Human Immunodeficiency Virus type 1 and Hepatitis C Virus. Comparing the groups based on their serological status, independently of being asymptomatic carriers, we observed a significant increase of PVL (p < 0.001) and LPA (p =0.001). However, when groups were stratified according to their clinical and serological status, there was no significant increase in Human T cell Leukemia Virus type 1 PVL and LPA. Conclusion: No significant increase of basal T-cell proliferation among Human T cell Leukemia Virus type 1 co-infected was observed. This interaction may be implicated in liver damage, worsening the prognosis of co-infected patients or, on the contrary, inducing a higher spontaneous clearance of Hepatitis C Virus infection in Human T cell Leukemia Virus type 1 co-infected patients. (C) 2018 Sociedade Brasileira de Infectologia.
Palavras-chave
HCV, HTLV-1, HIV-1, T-cell proliferation
Referências
- Assone T, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003199
- Bahia F, 2011, JAIDS-J ACQ IMM DEF, V57, pS202, DOI 10.1097/QAI.0b013e31821e9a1e
- Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
- Benard G, 1996, AM J TROP MED HYG, V54, P7, DOI 10.4269/ajtmh.1996.54.7
- Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177
- Brites C, 2009, AIDS REV, V11, P8
- Brites-Alves C, 2015, J IMMUNOL RES, V2015
- Cardoso DF, 2009, REV I MED TROP, V51, P325, DOI [10.1590/S0036-46652009000600004, 10.1590/S0036-46652009000600003]
- Casoli C, 2007, AIDS REV, V9, P140
- Casseb J, 1997, CLIN INFECT DIS, V25, P1259, DOI 10.1086/516969
- Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1
- Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
- Forlani G, 2014, METHODS MOL BIOL, V1087, P299, DOI 10.1007/978-1-62703-670-2_24
- Fujiyoshi T, 1999, AIDS RES HUM RETROV, V15, P1235, DOI 10.1089/088922299310124
- Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
- HARADA S, 1981, MICROBIOL IMMUNOL, V25, P23, DOI 10.1111/j.1348-0421.1981.tb00003.x
- HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
- Hoshino H, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00222
- KAMIHIRA S, 1991, JPN J MED, V30, P492
- Le Marchand C, 2015, BRAZ J INFECT DIS, V19, P486, DOI 10.1016/j.bjid.2015.06.007
- Lechmann M, 1996, HEPATOLOGY, V24, P790
- Matsuzaki T, 2001, J NEUROVIROL, V7, P228
- Montanheiro PA, 2009, SCAND J IMMUNOL, V70, P403, DOI 10.1111/j.1365-3083.2009.02291.x
- Montanheito PA, 2005, BRAZ J MED BIOL RES, V38, P1643, DOI 10.1590/S0100-879X2005001100011
- Moreira M, 2013, BRAZ J INFECT DIS, V17, P661, DOI 10.1016/j.bjid.2013.04.009
- Moxoto I, 2007, REV SOC BRAS MED TRO, V40, P37, DOI 10.1590/S0037-86822007000100007
- Norrgren H, 2010, INT J INFECT DIS, V14, pE142, DOI 10.1016/j.ijid.2009.11.040
- Olah I, 2007, SCAND J IMMUNOL, V65, P577, DOI 10.1111/j.1365-3083.2007.01941.x
- Oo Z, 2015, J MED VIROL, V87, P790, DOI 10.1002/jmv.24070
- Pinheiro SRAA, 2006, AM J OPHTHALMOL, V142, P811, DOI 10.1016/j.ajo.2006.06.013
- Posada-Vergara Maria Paulina, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P207, DOI 10.1590/S0036-46652006000400006
- Scapellato PG, 2003, JAIDS-J ACQ IMM DEF, V33, P279, DOI 10.1097/00126334-200306010-00028
- SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
- Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
- Stuver SO, 2000, J INFECT DIS, V182, P379, DOI 10.1086/315667